James E. Flynn and his fund, Deerfield Management, have disclosed a stake in Audentes Therapeutics Inc (NASDAQ:BOLD), a company that has recently closed its initial public offering. According to a filing with the Securities and Exchange Commission, Flynn and Deerfield hold roughly 1.4 million shares, which account for some 6.68% of the company’s outstanding stock.
Audentes Therapeutics Inc (NASDAQ:BOLD) is a biotechnology company that aims to develop gene therapy for various rare diseases. The company sold 5 million shares at $15 apiece in its initial offering, raising $75 million that it plans to invest in its research work. Among the main conditions it is now studying are X-Linked myotubular myopathy, Crigler-Najjar Syndrome, and Pompe disease. The drug candidates for these three conditions are expected to produce preliminary results from their first trials during the second half of 2017.
Samuel Isaly‘s OrbiMed Advisors had also invested in Audentes Therapeutics Inc (NASDAQ:BOLD) before the initial public offering and was the largest shareholder with a 29.8% stake prior to the offering. Overall, since its inception in 2012, Audentes Therapeutics has raised $135.8 million in equity financing from various venture capitalists and private investors, as well as hedge funds.
RAJ CREATIONZS / shutterstock.com
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Mgmt | 0 | 514,424 | 0 | 514,424 | 514,424 | 2.45% |
| Deerfield Management Company | 0 | 1,403,654 | 0 | 1,403,654 | 1,403,654 | 6.68% |
| Deerfield Mgmt III | 0 | 889,230 | 0 | 889,230 | 889,230 | 4.23% |
| Deerfield Special Situations Fund | 0 | 514,424 | 0 | 514,424 | 514,424 | 2.45% |
| Deerfield Private Design Fund III | 0 | 889,230 | 0 | 889,230 | 889,230 | 4.23% |
| James E. Flynn | 0 | 1,403,654 | 0 | 1,403,654 | 1,403,654 | 6.68% |
Follow James E. Flynn's Deerfield Management
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 14 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ) *
Audentes Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
05070R104
(CUSIP Number)
July 25, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 11 Pages)
__________________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 2 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 514,424 (1) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 514,424 (1) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 514,424 (1) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.45% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
__________________
(1) Comprised of Common Stock held by Deerfield Special Situations Fund, L.P. of which Deerfield Mgmt, L.P. is the general partner.
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 3 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Management Company, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 1,403,654 (2) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 1,403,654 (2) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,403,654 (2) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.68% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
__________________
(2) Comprised of Common Stock held by Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P. of which Deerfield Management Company, L.P. is the investment advisor.
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 4 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt III, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 889,230 (3) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 889,230 (3) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 889,230 (3) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.23% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
_________________
(3) Comprised of Common Stock held by Deerfield Private Design Fund III, L.P. of which Deerfield Mgmt III, L.P. is the general partner.
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 5 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Special Situations Fund, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 514,424 | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 514,424 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 514,424 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.45% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 6 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Private Design Fund III, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 889,230 | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 889,230 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 889,230 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.23% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 7 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) James E. Flynn | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION United States | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 1,403,654 (4) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 1,403,654 (4) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,403,654 (4) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.68% | ||
| 12. | TYPE OF REPORTING PERSON* IN | ||
__________________
(4) Comprised of Common Stock held by Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P.
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 8 of 11 |
| Item 1(a). | Name of Issuer: | |
| Audentes Therapeutics, Inc. | ||
| Item 1(b). | Address of Issuer’s Principal Executive Offices: | |
| 600 California Street, 17th Floor San Francisco, CA 94108 | ||
| Item 2(a). | Name of Person Filing: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Private Design Fund III, L.P. | ||
| Item 2(b). | Address of Principal Business Office, or if None, Residence: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Private Design Fund III, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 | ||
| Item 2(c). | Citizenship: | |
| Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P. – Delaware limited partnerships; James E. Flynn – United States citizen | ||
| Item 2(d). | Title of Class of Securities: | |
| Common Stock, par value $0.00001 per share | ||
| Item 2(e). | CUSIP Number: | |
| 05070R104 | ||
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| (a) | o | Broker or dealer registered under Section 15 of the Exchange Act. | |
| (b) | o | Bank as defined in Section 3(a)(6) of the Exchange Act. | |
| (c) | o | Insurance company as defined in Section 3(a)(19) of the Exchange Act. | |
| (d) | o | Investment company registered under Section 8 of the Investment Company Act. |
| (e) | o | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
| (f) | o | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); | |
| (g) | o | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); |
| (h) | o | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; |
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 9 of 11 |
| (i) | o | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; |
| (j) | o | A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); |
| |
| (k) | o | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). |
If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________
| Item 4. | Ownership. |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
| (a) | Amount beneficially owned**: | ||
| Deerfield Mgmt, L.P. – 514,424 shares Deerfield Mgmt III, L.P. – 889,230 shares Deerfield Management Company, L.P. – 1,403,654 shares Deerfield Special Situations Fund, L.P. – 514,424 shares Deerfield Private Design Fund III, L.P. – 889,230 shares James E. Flynn – 1,403,654 shares | |||
| (b) | Percent of class**: | ||
| Deerfield Mgmt, L.P. – 2.45% Deerfield Mgmt III, L.P. – 4.23% Deerfield Management Company, L.P. – 6.68% Deerfield Special Situations Fund, L.P. – 2.45% Deerfield Private Design Fund III, L.P. – 4.23% James E. Flynn – 6.68% |
| (c) | Number of shares as to which such person has**: | ||||
| (i) | Sole power to vote or to direct the vote: | All Reporting Persons – 0 | |||
| (ii) | Shared power to vote or to direct the vote: | Deerfield Mgmt, L.P. – 514,424 shares Deerfield Mgmt III, L.P. – 889,230 shares Deerfield Management Company, L.P. – 1,403,654 shares Deerfield Special Situations Fund, L.P. – 514,424 shares Deerfield Private Design Fund III, L.P. – 889,230 shares James E. Flynn – 1,403,654 shares | |||
| (iii) | Sole power to dispose or to direct the disposition of: | All Reporting Persons – 0 | |||
| (iv) | Shared power to dispose or to direct the disposition of: | Deerfield Mgmt, L.P. – 514,424 shares Deerfield Mgmt III, L.P. – 889,230 shares Deerfield Management Company, L.P. – 1,403,654 shares Deerfield Special Situations Fund, L.P. – 514,424 shares Deerfield Private Design Fund III, L.P. – 889,230 shares James E. Flynn – 1,403,654 shares |
**See footnotes on cover pages which are incorporated by reference herein.
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 10 of 11 |
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following o.
| | |
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
| | N/A |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
| | N/A |
| Item 8. | Identification and Classification of Members of the Group. |
If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.
| | See Exhibit B |
| Item 9. | Notice of Dissolution of Group. |
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
| | N/A |
| Item 10. | Certifications. |
“By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.”
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 11 of 14 – SEC Filing
| CUSIP No. | 05070R104 | 13G | Page 11 of 11 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Date: July 25, 2016
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 12 of 14 – SEC Filing
Exhibit List
Exhibit A. Joint Filing Agreement.
Exhibit B. Item 8 Statement.
Exhibit C. Power of Attorney (1).
(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 13 of 14 – SEC Filing
Exhibit A
Joint Filing Agreement
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock, par value $0.00001 of Audentes Therapeutics, Inc. shall be filed on behalf of the undersigned.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 14 of 14 – SEC Filing
Exhibit B
Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.